The purpose of ordering for ferrous sulfate. Case summary: J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Question

Want to see the full answer?

Answer 1

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

Related research design to answer the clinical question “How registered nurses accurately measure respiratory rates in performing vital sign assessments in hospital?” Provide article title, purpose/aim, methods and key finding

Anything else I should add to this slide and notes? Can you also put the notes into paragraphs with the changes?

How are the nervous and musculoskeletal systems interrelated? How do central nervous system abnormalities and damage to the musculoskeletal system affect mobility? Please cite in text source and list references

Answer 2

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 3

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 4

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 5

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 6

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 7

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 8

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 9

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 10

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 11

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 12

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 13

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 14

Expert Solution & Answer

Answer 15

Expert Solution & Answer

Answer 16

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 17

Ch. 54 - Prob. 1O Ch. 54 - Prob. 2O Ch. 54 - Prob. 3O Ch. 54 - Prob. 4O Ch. 54 - Prob. 1CS Ch. 54 - Prob. 1NERQ Ch. 54 - Prob. 2NERQ Ch. 54 - Prob. 3NERQ Ch. 54 - Prob. 4NERQ Ch. 54 - Prob. 5NERQ

Want to see the full answer?

Chapter 54 Solutions